Viewing data from:

VERSAPEN

NDA

HETACILLIN | N050060 | BRISTOL LABORATORIES INC DIV BRISTOL MYERS CO

2 strengths0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

API Supply Chain0 active DMFs2 inactive

0 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

BARCELONETA INC DIV BRISTOL MYERSInactiveHETACILLIN ACID

DMF 134221998

BRISTOL MYERS SQUIBB COInactiveHETACILLIN

DMF 134271998

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 112.5MG AMPICIL/5ML

0 patents0 exclusivities▴

FOR SUSPENSION;ORAL | Approved: Approved Prior to Jan 1, 1982

No patent or exclusivity listings for this strength.

#003 — EQ 112.5MG AMPICIL/ML

0 patents0 exclusivities▾

FOR SUSPENSION;ORAL | Approved: Approved Prior to Jan 1, 1982